What is Xeltis?
Xeltis operates at the intersection of medical technology and cardiovascular health, developing advanced polymer-based restorative devices. These devices aim to provide long-term solutions for patients requiring cardiovascular interventions, such as heart valve replacement and vascular grafts. Originating from the merger of two university spin-offs in the Netherlands and USA, Xeltis is positioned to address critical unmet needs in cardiovascular care. The company's technology is currently investigational and not yet approved for sale, indicating a strong focus on research and development to bring its novel solutions to market.
How much funding has Xeltis raised?
Xeltis has raised a total of $90.1M across 3 funding rounds:
Series B
$3.3M
Series C
$52.8M
Series D
$34M
Series B (2015): $3.3M with participation from Kurma Partners, Life Sciences Partners, and VI Partners
Series C (2017): $52.8M led by Kurma Partners, Life Sciences Partners, Ysios Capital, and VI Partners
Series D (2023): $34M supported by Invest-NL, EQT Life Sciences, and Grand Pharmaceutical Group
Key Investors in Xeltis
Kurma Partners
Kurma Partners is a prominent player in funding healthcare and biotechnology ventures across Europe, specializing in investing at various maturity stages. They transform disruptive scientific discoveries into advanced medical solutions, focusing on severe diseases with high unmet medical needs.
Life Sciences Partners
European Biotech Acquisition Corp. intends to effect a merger, share exchange, asset acquisition, or similar business combination with one or more businesses or entities, focusing on the biotech sector.
Ysios Capital
Ysios Capital is a leading life sciences venture capital firm that invests in highly innovative biotechnology companies worldwide, providing resources to ventures focused on developing novel therapies for high unmet medical needs.
What's next for Xeltis?
The recent major strategic investment signals a pivotal growth phase for Xeltis, likely enabling the company to advance its clinical trials, scale manufacturing capabilities, and pursue regulatory approvals. This capital infusion is crucial for a company in the clinical-stage development phase, suggesting a strategic push towards commercialization. Future developments will likely focus on demonstrating the long-term efficacy and safety of their restorative devices, paving the way for broader adoption in the cardiovascular treatment landscape.
See full Xeltis company page
